Reproductive Factors, Hormonal Contraception, and Risk of Uterine Leiomyomata in African-American Women: A Prospective Study

American Journal of Epidemiology

Volumn 159, Issue 2, 2004, Pages 113-123

  Wise, Lauren A ^a,b   Palmer, Julie R ^b   Harlow, Bernard L ^a,c   Spigelman, Donna ^a   Stewart, Elizabeth A ^c   Adams Campbell, Lucile L ^d   Rosenberg, Lynn ^b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BOSTON UNIVERSITY   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HOWARD UNIVERSITY CANCER CENTER   (United States)

Author keywords

Blacks; Contraceptives, oral; Female; Leiomyoma; Premenopause; Prospective studies; Reproduction; Uterine neoplasms

Indexed keywords

GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT;

CONTRACEPTIVE USE; ETHNICITY; HEALTH RISK; RISK FACTOR; WOMENS HEALTH;

ADULT; AGED; ALCOHOL CONSUMPTION; ANAMNESIS; ARTICLE; BODY MASS; CANCER INCIDENCE; CANCER RISK; CIGARETTE SMOKING; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; HIGH RISK POPULATION; HORMONAL CONTRACEPTION; HUMAN; HYSTERECTOMY; INFERTILITY; MAJOR CLINICAL STUDY; MENARCHE; NEGRO; OBESITY; PARITY; PREMENOPAUSE; PROSPECTIVE STUDY; QUESTIONNAIRE; REGRESSION ANALYSIS; REPRODUCTION; RISK ASSESSMENT; SELF REPORT; SIDE EFFECT; SMOKING HABIT; UTERINE LEIOMYOMATA; UTERUS MYOMA;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGE FACTORS; AGED; COHORT STUDIES; CONTRACEPTIVES, ORAL; FEMALE; HUMANS; LEIOMYOMA; MENARCHE; MIDDLE AGED; OBESITY; PARITY; PREMENOPAUSE; PROGESTERONE CONGENERS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RISK FACTORS; UTERINE NEOPLASMS;

NORTH AMERICA; UNITED STATES;

EID: 0347342425     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/aje/kwh016     Document Type: Article

References (63)

1. Buttram VC, Reiter RC. Uterine leiomyomata: etiology, symptomatology, and management. Fertil Steril 1981;36:433-45.
2. Coronado GD, Marshall LM, Schwartz SM. Complications in pregnancy, labor, and delivery with uterine leiomyomas: a population-based study. Obstet Gynecol 2000;95:764-9.
3. Stewart EA. Uterine fibroids. Lancet 2001;357:293-8.
4. Velebil P, Wingo PA, Xia Z, et al. Rate of hospitalization for gynecologic disorders among reproductive-age women in the United States. Obstet Gynecol 1995;86:764-9.
5. Wilcox LS, Koonin LM, Pokras R, et al. Hysterectomy in the United States, 1988-1990. Obstet Gynecol 1994;83:549-55.
6. Farquhar CM, Steiner CA. Hysterectomy rates in the United States 1990-1997. Obstet Gynecol 2002;99:229-34.
7. Marshall LM, Spiegelman D, Barbieri RL, et al. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol 1997;90:967-73.
8. Brett KM, Marsh JV, Madans JH. Epidemiology of hysterectomy in the United States: demographic and reproductive factors in a nationally representative sample. J Womens Health 1997;6:309-16.
9. Baird DD, Dunson DB, Hill MC, et al. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 2003;188:100-7.
10. Kjerulff KH, Langenberg P, Seidman JD, et al. Uterine leiomyomas: racial differences in severity, symptoms, and age at diagnosis. J Reprod Med 1996;41:483-90.
11. Rein MS. Advances in uterine leiomyoma research: the progesterone hypothesis. Environ Health Perspect 2000;108:791-3.
12. Parazzini F, Negri E, La Vecchia C, et al. Reproductive factors and risk of uterine fibroids. Epidemiology 1996;7:440-2.
13. Romieu I, Walker AM, Jick S. Determinants of uterine fibroids. Post Marketing Surveill 1991;5:119-33.
14. Ross RK, Pike MC, Vessey MP, et al. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. BMJ (Clin Res Ed) 1986;293:359-62.
15. Chiaffarino F, Parazzini F, La Vecchia C, et al. Use of oral contraceptives and uterine fibroids: results from a case-control study. Br J Obstet Gynecol 1999;106:857-60.
16. Faerstein E, Szklo M, Rosenshein N. Risk factors for uterine leiomyoma: a practice-based case-control study. I. African-American heritage, reproductive history, body size, and smoking. Am J Epidemiol 2001;153:1-10.
17. Marshall LM, Spiegelman D, Goldman MB, et al. A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. Fertil Steril 1998; 70:432-9.
18. Lumbiganon P, Rugpao S, Phandhu-fung S, et al. Protective effect of depot-medroxyprogesterone acetate on surgically treated uterine leiomyomas: a multicentre case-control study. Br J Obstet Gynecol 1996;103:909-14.
19. Samadi AR, Lee NC, Flanders WD, et al. Risk factors for self-reported uterine fibroids: a case-control study. Am J Public Health 1996;86:858-62.
20. Parazzini F, La Vecchia C, Negri E, et al. Epidemiologic characteristics of women with uterine fibroids: a case-control study. Obstet Gynecol 1988;72:853-7.
21. Ramcharan S, Pellegrin FA, Ray RM, et al. The Walnut Creek Contraceptive Drug Study. A prospective study of the side effects of oral contraceptives. Volume III, an interim report: a comparison of disease occurrence leading to hospitalization or death in users and nonusers of oral contraceptives. J Reprod Med 1980;25(suppl):345-72.
22. Rosenberg L, Adams-Campbell LL, Palmer JR. The Black Women's Health Study: a follow-up study for causes and preventions of illness. J Am Med Womens Assoc 1995;50:56-8.
23. Schwartz SM, Marshall LM, Baird DD. Epidemiologic contributions to understanding the etiology of uterine leiomyomata. Environ Health Perspect 2000;108:821-7.
24. Dueholm M, Lundorf E, Hansen ES, et al. Accuracy of magnetic resonance imaging and transvaginal ultrasonography in the diagnosis, mapping, and measurement of uterine myomas. Am J Obstet Gynecol 2001;186:409-15.
25. Loutradis D, Antsaklis A, Creatsas G, et al. The validity of gynecological ultrasonography. Gynecol Obstet Invest 1990; 29:47-50.
26. Hillard PA. Benign disease of the female reproductive tract: symptoms and signs. In: Berek J, ed. Novak's gynecology. Baltimore, MD: Williams & Wilkins, 1996:331-97.
27. Dickey RP. Managing contraceptive pill patients. 10th ed. Dallas, TX: EMIS, Inc, 2000.
28. Carr BR. Re-evaluation of oral contraceptive classifications. Int J Fertil 1997;42(suppl 1):133-44.
29. SAS Institute, Inc. SAS/STAT user's guide. Version 8.02. Cary, NC: SAS Institute, Inc. 2002.
30. Hertzmark E, Spiegelman D. The SAS MPHREG macro. Boston, MA: Channing Laboratory, 2001.
31. Therneau TM. Extending the Cox model. In: Lin DY, Fleming TR, eds. Proceedings of the First Seattle Symposium in Biostatistics: Survival Analysis. New York, NY: Springer Verlag, 1997.
32. Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med 1989:8:551-61.
33. Greenland S. Modeling and variable selection in epidemiologic analysis. Am J Public Health 1989;79:340-9.
34. Breslow NE, Day NE. Statistical methods in cancer research. Vol II. The design and analysis of cohort studies. Lyon, France: International Agency for Research on Cancer, 1987. (IARC scientific publication no. 82).
35. Snow R. Body fat, fat topography and endogenous dynamics. In: Snow R, Hall P, eds. Steroid contraceptives and women's response. New York, NY: Plenum Press, 1994:179-86.
36. Sarkola T, Makisalo H, Fukunaga T, et al. Acute effect of alcohol on estradiol, estrone, progesterone, prolactin, cortisol, and luteinizing hormone in premenopausal women. Alcohol Clin Exp Res 1999;23:976-82.
37. Baird DD, Dunson DB. Why is parity protective for uterine fibroids? Epidemiology 2003;14:247-50.
38. Windham GC, Elkin E, Fenster L, et al. Ovarian hormones in premenopausal women: variation by demographic, reproductive and menstrual cycle characteristics. Epidemiology 2002; 13:675-84.
39. Apter D, Reinila M, Vihko R. Some endocrine characteristics of early menarche, a risk factor for breast cancer, are preserved into adulthood. Int J Cancer 1989;44:783-7.
40. MacMahon B, Trichopoulos D, Brown J, et al. Age at menarche, urine estrogens and breast cancer risk. Int J Cancer 1982;30:427-31.
41. Chen CR, Buck GM, Courey NG, et al. Risk factors for uterine fibroids among women undergoing tubal sterilization. Am J Epidemiol 2001;153:20-6.
42. Musey VC, Collins DC, Musey PI, et al. Age-related changes in the female hormonal environment during reproductive life. Am J Obstet Gynecol 1987;157:312-17.
43. Dorgan JF, Reichman ME, Judd JT, et al. Relationships of age and reproductive characteristics with plasma estrogen and androgens in premenopausal women. Cancer Epidemiol Biomarkers Prev 1995;4:381-6.
44. Bernstein L, Pike MC, Ross RK, et al. Estrogen and sex hormone-binding globulin levels in nulliparous and parous women. J Natl Cancer Inst 1985;74:741-5.
45. Musey VC, Collins DC, Brogan DR, et al. Long term effects of a first pregnancy on the hormonal environment: estrogens and androgens. J Clin Endocrinol Metab 1987;64:111-18.
46. Musey VC, Collins DC, Musey PI, et al. Long-term effect of a first pregnancy on the secretion of prolactin. N Engl J Med 1987;316:229-34.
47. Mora S, Diehl T, Stewart EA, et al. Prolactin is an autocrine growth regulator for human myometrial and leiomyoma cells. (Abstract). J Soc Gynecol Invest 1995;2:396.
48. Kawaguchi K, Fujii S, Konishi I, et al. Immunohistochemical analysis of oestrogen receptors, progesterone receptors and Ki-67 in leiomyoma and myometrium during the menstrual cycle and pregnancy. Virchows Arch A Pathol Anat Histopathol 1991;419:309-15.
49. Walker CL, Cesen-Cummings K, Houle C, et al. Protective effect of pregnancy for development of uterine leiomyoma. Carcinogenesis 2001;22:2049-52.
50. Lambe M, Wuu J, Weiderpass E, et al. Childbearing at older age and endometrial cancer risk (Sweden). Cancer Causes Control 1999;10:43-9.
51. Wallach M, Grimes DA, eds. Modern oral contraception: updates from the Contraception Report. Totowa, NJ: Emron, 2000.
52. Althuis MD, Brogan DR, Coates RJ, et al. Hormonal content and potency of oral contraceptives and breast cancer risk among young women. Br J Cancer 2003;88:50-7.
53. Schildkraut JM, Calingaert B, Marchbanks PA, et al. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer Inst 2002;94:32-8.
54. Bouchard C, Brisson J, Fortier M, et al. Use of oral contraceptive pills and vulvar vestibulitis: a case-control study. Am J Epidemiol 2002;156:254-61.
55. Clark MK, Sowers MF, Levy BT, et al. Magnitude and variability of sequential estradiol and progesterone concentrations in women using depot medroxyprogesterone acetate for contraception. Fertil Steril 2001;75:871-7.
56. Mishell DR. Pharmacokinetics of depot medroxyprogesterone acetate contraception. J Reprod Med 1996;41:381-90.
57. Englund K, Blanck A, Gustavsson I, et al, Sex steroid receptors in human myometrium and fibroids: changes during the menstrual cycle and gonadotropin-releasing hormone treatment. J Clin Endocrinol Metab 1998;83:4092-6.
58. Hernan MA, Brumback B, Robins JM, Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 2000;11:561-70.
59. Biro FM, McMahon RP, Striegel-Moore R, et al. Impact of timing of pubertal maturation on growth in black and white female adolescents: the National Heart, Lung, and Blood Institute Growth and Health Study. J Pediatr 2001;138:636-43.
60. Lee PA, Guo SS, Kulin HE. Age of puberty: data from the United States of America. APMIS 2001;109:81-8.
61. Abma JC, Chandra A, Mosher WD, et al. Fertility, family planning, and women's health: new data from the 1995 National Survey of Family Growth. Vital Health Stat 23 1997;(19):1-114.
62. Anderson SE, Dallal GE, Must A. Relative weight and race influence average age at menarche: results from two nationally representative surveys of US girls studied 25 years apart. Pediatrics 2003;111:844-50.
63. Wu T, Mendola P, Buck GM. Ethnic differences in the presence of secondary sex characteristics and menarche among US girls: the Third National Health and Nutrition Examination Survey, 1988-1994. Pediatrics 2002;110:752-7.